GSK’s Nucala approved in China for COPD with high eosinophils
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The company previously completed a $150 million venture investment, acquisition, and recapitalization
CystoSmart, an AI tool designed to detect bladder tumors during screening and surveillance cystoscopy, is brand-agnostic and works with flexible, rigid, and single-use scopes
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
He noted the enduring relevance of Siddha medicine as “a comprehensive, preventive and sustainable healthcare system in the contemporary world
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Subscribe To Our Newsletter & Stay Updated